Presentation is loading. Please wait.

Presentation is loading. Please wait.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Similar presentations


Presentation on theme: "Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in."— Presentation transcript:

1 Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in patients with cancer. Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in patients with cancer. CANTHANOX, Secondary Prevention Trial of Venous Thromboembolism With Enxoaparin; CATCH, Comparison of Acute Treatments in Cancer Hemostasis; CLOT, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer; LITE, Long-Term Innohep Treatment Evaluation; LMWH, low-molecular-weight heparin; ONCENOX, Oncology and Enoxaparin; VKA, vitamin K antagonist; VTE, venous thromboembolism. Cihan Ay et al. ESMO Open 2017;2:e000188 Copyright © European Society for Medical Oncology. All rights reserved.


Download ppt "Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in."

Similar presentations


Ads by Google